Skip to content
MarketScale
‹ Back to IndustriesSciences

The Future of Composites: Empowering Successful Space Missions.

Rocket launches and space missions are natural outgrowths of thousands of years of experimentation and research. They are complex and very expensive, but we keep having them, with hundreds of satellites being launched annually. According to GeospatialWorld, the year 2022 has so far witnessed the maximum number of orbital and suborbital launches, amounting to 155…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Filament WindingKevin LowdermilkRoth CompositesSatellite Launch
Share

Key takeaways

01

Rocket launches and space missions are natural outgrowths of thousands of years of experimentation and research.

02

They are complex and very expensive, but we keep having them, with hundreds of satellites being launched annually.

03

According to GeospatialWorld, the year 2022 has so far witnessed the maximum number of orbital and suborbital launches, amounting to 155…

Rocket launches and space missions are natural outgrowths of thousands of years of experimentation and research. They are complex and very expensive, but we keep having them, with hundreds of satellites being launched annually. According to GeospatialWorld, the year 2022 has so far witnessed the maximum number of orbital and suborbital launches, amounting to 155 launches in total.

With how complex and expensive this process is, there are companies developing substitute materials for easier, more cost-effective rocket and satellite launches. How are these companies making rocket science out of nearly anything, and what process are they using to achieve their successes?

On this episode of the Vaya Space Podcast, the host, Michelle Dawn Mooney, brought on Kevin Lowdermilk, the CEO of Vaya Space; Hayley Nedbalski, Aeronautical Engineer III, Composites at Vaya Space; Rouven Weg, Sales Manager for Roth Composites Machinery; and Joe Jansen, National Sales Manager for Roth Composite Machinery of North America to talk about satellite launches, new build materials, the partnership between Vaya and Roth and how they have been empowering space missions.

“Vaya is primarily a satellite launch company. We leverage hybrid engine technology to safely, reliably, and cost-effectively put data satellites into precision orbits,” Kevin said.

“Roth is a family-owned company in Europe serving various businesses ranging from plastic technology, environmental solutions for businesses to customers and business to business sectors, and the manufacturing of different machinery equipment. We are one of the first companies in Europe to build dedicated equipment for filament winding,” Rouven answered.

“Composites are two-part material systems that consist of both fiber and a matrix or resin. They are combined in a certain ratio to form what we call laminate. They have an excellent strength-to-weight ratio compared to metals of the same thickness, which makes them ideal for our spacecraft systems,” Hayley added.

Mooney, Lowdermilk, Nedbalski, Weg, and Jansen also discussed:

  • What Roth is doing for Vaya Space
  • How Roth and Vaya’s partnership work and how it sets Vaya apart from other companies out there
  • The future of composites

“How does Vaya use composites?” Mooney asked. “Composites are used for large and small space structures. They can include lock tanks, gaskets, baskets, etc. A lot of our structures are going to be made from various manufacturing techniques, which include resin infusion, vacuum inflation, etc.,” Nedbalski responded.

What is Roth doing for Vaya Space? Mooney threw the question out to the guests to give a general idea.

Joe answered by saying, “Roth and Vaya came together as a need or requirement for filament winding equipment that we happily provided them.”

“We are always looking for performance, reliability, and cost advantages in building rockets, and Roth brings all those things to the table for us. The weight savings and improved strength they provide are really crucial and lead to much more payload, which is everything in our business,” Kevin added. “Space launch is expensive today, and this kind of relationship put us in a good place for a long time to continue to bring costs down and innovate. We are thrilled with the relationship.”

Kevin Lowdermilk is that Interim CEO of Vaya Space. He was the CFO of Strategic Partners, a company that provides operational and financial leadership to mid-market companies in multiple industries.

Hayley Nedbalski has a Bachelor of Science Degree in Aerospace Engineering with a concentration in Astronautics from Embry-Riddle Aeronautical University. She has worked in the composite design and manufacturing industry for over five years, designing and building composite parts such as hydrofoils, wing tips, and marine hulls, decks, and small parts.

Rouven Weg is the full-time sales manager for Roth Composites Machinery. He has a Master’s of Science from the Technische Hochschule Mittelhessen and a Bachelor’s of Engineering from the PFH Private Hochschule Göttingen.

Joe Jansen is the National Sales Manager of Roth Composite Machinery. He is well-respected throughout the composite industry and has a wealth of industry knowledge and experience. Jansen is responsible for providing and assisting customers with training on the operation, programming, repair, and maintenance of Roth’s winding machines. He is the man to go to about the correct manufacturing methods for Roth’s products, as well as recommendations for further equipment, materials, and suppliers.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512